Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features

Journal of the American Academy of Dermatology(2020)10.1016/j.jaad.2020.04.105Source: DataRank Database

Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features is a research paper published in Journal of the American Academy of Dermatology (2020). On theSindex it has a DataRank of 0. It has been cited 170 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access170 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)OA: greenTopics (59)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Aren T. Vierra,Jillian Wong Millsop ORCID,Mario E. Lacouture ORCID,Maija Kiuru ORCID,Samantha R. Ellis

Live enrichment

PubMed:32360716 PMC:PMC7492441

National Cancer Institute

Grant: P30-CA0-08748

National Cancer Institute

Grant: U01AR077511

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: K23AR074530

NIAID NIH HHS

Grant: U01 AI147462

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 1U01AR077511-01

Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy

Dermatology Foundation

National Institutes of Health

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7492441

publisherhttps://api.elsevier.com/content/article/PII:S0190962220307210?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0190962220307210?httpAccept=text/plain

https://doi.org/10.1016/j.jaad.2020.04.105

https://europepmc.org/articles/pmc7492441?pdf=render

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

KeratinocytesHumansNevus, PigmentedStevens-Johnson SyndromePanniculitisDrug EruptionsAlopeciaVitiligoPruritusLichenoid EruptionsPsoriasisAcantholysisPemphigoid, BullousImmune Checkpoint Inhibitors

Keywords

ToxicityImmunotherapyCTLA-4RaSHCutaneousPD-L1SKinBullous PemphigoidIpilimumabAdverse EventPd1NivolumabCheckpoint InhibitorLichenoid DermatitisPembrolizumabAtezolizumabAvelumabDurvalumabKeratinocytesLichenoid EruptionsPanniculitisOncology and CarcinogenesisImmunologyClinical SciencesVitiligoPigmentedPemphigoid, BullousHumansPsoriasisNevusImmune Checkpoint InhibitorsCancerNevus, PigmentedBiomedical and Clinical SciencesInflammatory and immune systemDermatology & Venereal DiseasesPruritusBullousAlopeciaAcantholysisStevens-Johnson SyndromeDrug EruptionsPemphigoid

Sustainable Development Goals

SDG 3: 3. Good health

Related Papers (2)

Immune checkpoint inhibitor–related dermatologic adverse events

Journal of the American Academy of Dermatology(2020)

co-citedsame journal

10.1016/j.jaad.2020.03.132

First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors

Top 47%

0.385DataRank

JNCI Journal of the National Cancer Institute(2024)

co-cited

10.1093/jnci/djae297